The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
=== Neoantigens === Neoantigens are those that are entirely absent from the normal human genome. As compared with nonmutated self-proteins, neoantigens are of relevance to tumor control, as the quality of the T cell pool that is available for these antigens is not affected by central T cell tolerance. Technology to systematically analyze T cell reactivity against neoantigens became available only recently. Neoantigens can be directly detected and quantified.
The bar under the second fenestra has also been lost and the jaws have extreme flexibility allowing the snake to swallow its prey whole. Snakes lack moveable eyelids, the eyes being covered by transparent "spectacle" scales. They do not have eardrums but can detect ground vibrations through the bones of their skull. Their forked tongues are used as organs of taste and smell and some species have sensory pits on their heads enabling them to locate warm-blooded prey. Crocodilians are large, low-slung aquatic reptiles with long snouts and large numbers of teeth. The head and trunk are dorso-ventrally flattened and the tail is laterally compressed. It undulates from side to side to force the animal through the water when swimming. The tough keratinized scales provide body armour and some are fused to the skull. The nostrils, eyes and ears are elevated above the top of the flat head enabling them to remain above the surface of the water when the animal is floating. Valves seal the nostrils and ears when it is submerged. Unlike other reptiles, crocodilians have hearts with four chambers allowing complete separation of oxygenated and deoxygenated blood.
== Signs and symptoms == Adrenocortical carcinoma may present differently in children and adults. Most tumors in children are functional, and virilization is by far the most common presenting symptom(s), followed by Cushing's syndrome and precocious puberty. Among adults presenting with hormonal syndromes, Cushing's syndrome alone is most common, followed by mixed Cushing's and virilization (glucocorticoid and androgen overproduction). Feminization and Conn syndrome (mineralocorticoid excess) occur in less than 10% of cases. Rarely, pheochromocytoma-like hypersecretion of catecholamines has been reported in adrenocortical cancers. Nonfunctional tumors (about 40%, authorities vary) usually present with abdominal or flank pain, varicocele, and renal vein thrombosis or they may be asymptomatic and detected incidentally. All patients with suspected ACC should be carefully evaluated for signs and symptoms of hormonal syndromes. For Cushing's syndrome (glucocorticoid excess), these include weight gain, muscle wasting, purple lines on the abdomen, a fatty "buffalo hump" on the neck, a "moon-like" face, and thinning, fragile skin. Virilism (androgen excess) is most obvious in women, and may produce excess facial and body hair, acne, enlargement of the clitoris, deepening of the voice, coarsening of facial features, cessation of menstruation.
=== Rum trading === Grose also relaxed Phillip's prohibition on trading of rum, sometimes a generic term for any form of distilled beverage, usually made from wheat, commonly from Bengal. The colony, like many British territories at the time, was short of coins, and rum soon became the medium of trade. The officers of the Corps were able to use their position and wealth to buy all the imported rum and then exchange it for goods and labour at very favourable rates, earning the Corps the nickname "The Rum Corps". By 1793 stills were being imported and grain was being used to make rum, exacerbating the shortage of grain. Due to poor health Grose returned to England in December 1794 and Captain William Paterson assumed temporary command until a permanent replacement, Governor John Hunter, arrived in September 1795. Paterson had obtained his commission with the backing of Sir Joseph Banks because he was interested in natural history and would explore and collect samples for Banks and the Royal Society. Governor Hunter attempted unsuccessfully to use the troops of the Corps to guard imported rum and stop the officers from buying it up. Attempts to stop the importation were also thwarted by the failure of other governments to co-operate and by the Corps' officers chartering of a Danish ship to bring in a large shipment of rum from India. Hunter also tried to start up a public store with goods from England to provide competition and stabilise the price of goods, but Hunter was not a good businessman and supplies were too erratic.
Enzymes that transfer aldehyde or ketone groups and included in EC 2.2. This category consists of various transketolases and transaldolases. Transaldolase, the namesake of aldehyde transferases, is an important part of the pentose phosphate pathway. The reaction it catalyzes consists of a transfer of a dihydroxyacetone functional group to glyceraldehyde 3-phosphate (also known as G3P). The reaction is as follows: sedoheptulose 7-phosphate + glyceraldehyde 3-phosphate
Sources: en.wikipedia.org
== In polymer physics == In some scientific areas such as polymer physics, one may consider a chain of points and links between consecutive points. If the points are sequentially numbered and located at positions r1, r2, r3, etc. then bond vectors are defined by u1=r2−r1, u2=r3−r2, and ui=ri+1−ri, more generally. This is the case for kinematic chains or amino acids in a protein structure. In these cases, one is often interested in the half-planes defined by three consecutive points, and the dihedral angle between two consecutive such half-planes. If u1, u2 and u3 are three consecutive bond vectors, the intersection of the half-planes is oriented, which allows defining a dihedral angle that belongs to the interval (−π, π]. This dihedral angle is defined by
From 2010 to 2015 and again in 2016 and in 2018, some prisoners in the US refused to work, protesting for better pay, better conditions, and for the end of forced labor. Strike leaders were punished with indefinite solitary confinement. Forced prison labor occurs in both government-run prisons and private prisons. CoreCivic and GEO Group constitute half the market share of private prisons, and they made a combined revenue of $3.5 billion in 2015. The value of all labor by inmates in the United States is estimated to be in the billions. In California, 2,500 incarcerated workers fought wildfires for only $1 per hour through the CDCR's Conservation Camp Program, which saves the state as much as $100 million a year.
== Air quality == The Air Quality Life Index (AQLI) by the Energy Policy Institute at the University of Chicago (EPIC) tracks ambient particulate pollution, measured in PM2.5, and calculates its impact on life expectancy. The World Health Organization's guideline is 10 micrograms per cubic meter (μg/m3). The 2016 index ranks Thailand as the seventh most polluted of 226 nations (1=highest μg/m3; 226=lowest μg/m3). Other ASEAN nations ranked were Laos, 8; Singapore, 12; Myanmar, 18; Indonesia, 19; Vietnam, 24; Malaysia, 41; Cambodia, 43; Brunei, 121; Philippines, 132.
Emus are farmed primarily for their meat, leather, feathers and oil, and 95% of the carcass can be used. Emu meat is a low-fat product (less than 1.5% fat), and is comparable to other lean meats. Most of the usable portions (the best cuts come from the thigh and the larger muscles of the drum or lower leg) are, like other poultry, dark meat; emu meat is considered for cooking purposes by the US Food and Drug Administration to be a red meat because its red colour and pH value approximate that of beef, but for inspection purposes it is considered to be poultry. Emu fat is rendered to produce oil for cosmetics, dietary supplements, and therapeutic products. The oil is obtained from the subcutaneous and retroperitoneal fat; the macerated adipose tissue is heated and the liquefied fat is filtered to get a clear oil. This consists mainly of fatty acids of which oleic acid (42%), linoleic and palmitic acids (21% each) are the most prominent components. It also contains various anti-oxidants, notably carotenoids and flavones. There is some evidence that the oil has anti-inflammatory properties; however, there have not yet been extensive tests, and the USDA regards pure emu oil as an unapproved drug and highlighted it in a 2009 article entitled "How to Spot Health Fraud". Nevertheless, the oil has been linked to the easing of gastrointestinal inflammation, and tests on rats have shown that it has a significant effect in treating arthritis and joint pain, more so than olive or fish oils.
The two substrates of this enzyme are cis-1,2-dihydrocatechol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are catechol, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is cis-1,2-dihydrobenzene-1,2-diol:NAD+ oxidoreductase. Other names in common use include cis-benzene glycol dehydrogenase, cis-1,2-dihydrocyclohexa-3,5-diene (nicotinamide adenine, and dinucleotide) oxidoreductase. This enzyme participates in 4 metabolic pathways: gamma-hexachlorocyclohexane degradation, toluene and xylene degradation, naphthalene and anthracene degradation, and styrene degradation.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.